Why it matters

The HIV Medicine Association continues its decade-long lobbying push at a critical moment. Federal HIV programs face unprecedented threats from proposed budget cuts and agency reorganizations. The organization’s $50,000 quarterly investment comes as Congress debates eliminating CDC HIV prevention funding entirely.

By the numbers

  • Current spending: $50,000 in Q2 2025 to Collier Collective LLC
  • Historical investment: $860,000 total since 2015 partnership began
  • Consistent advocacy: 43 lobbying disclosures over nearly a decade
  • Lead lobbyist: Jennifer Collier, firm founder with extensive health policy experience

Broader context

Rep. Maxine Waters condemned proposals that would “dismantle our nation’s HIV/AIDS programs.” Congressional leaders report that CDC HIV prevention funding faces elimination. The H.R. 4 Rescissions Act threatens global health funding with domestic spillover effects.

The agenda

HIVMA is lobbying for robust appropriations to protect HIV programs. The organization focuses on Ryan White HIV/AIDS Program funding and the Ending the HIV Epidemic initiative. Budget/Appropriations appears in virtually all HIVMA filings through Collier Collective.

Competitive landscape

Other HIV organizations are mobilizing alongside HIVMA. The AIDS Vaccine and Advocacy Coalition spent $240,000 on advocacy. PrEP4All invested $186,000 since 2022. The Partnership to End HIV, AIDS and Hepatitis continues multi-issue advocacy efforts.

Between the lines

The HHS FY2026 Budget Hearing revealed sweeping reorganization plans threatening CDC and NIH. Rep. Pete Aguilar announced $5.3M for San Bernardino HIV programs. Multiple resolutions including S.Res.171 explicitly endorse Ryan White and CDC funding.

The bottom line

HIVMA’s sustained lobbying investment reflects the high stakes of current appropriations battles. With federal HIV programs facing elimination, the organization’s advocacy through experienced representatives becomes essential. Success will be measured in continued access to prevention and treatment services.

Spot something wrong? Report an issue with this article